Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Iznaga

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Methods and Findings in Experimental and Clinical Pharmacology|January 6, 2005
(99m)Tc-labeled murine ior C5 monoclonal antibody in colorectal carcinoma patients: pharmacokinetics, biodistribution, absorbed radiation doses to normal organs and tissues and tumor localizationN Iznaga-Escobar, M Ramos-Suzarte, A Morales-Morales, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 26, 1998
Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearancesN Iznaga-Escobar, L A Torres Arocha, A Morales Morales, et al.
Nuclear Medicine and Biology|February 18, 1998
Technetium-99m direct radiolabeling of monoclonal antibody ior egf/r3A A Morales, F Z Crespo, G N Gandolff, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 31, 2001
Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptorT Crombet, O Torres, E Neninger, et al.
International Immunopharmacology|May 12, 2004
Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell lineM Tejuca, I Díaz, R Figueredo, et al.
Nuclear Medicine and Biology|April 25, 2000
Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studiesA A Morales, J Ducongé, D Alvarez-Ruiz, et al.
Journal of Immunological Methods|September 13, 1996
Multianalytical system (MAS): software for enzyme-linked immunosorbent assay (ELISA) data processing with applications to screening and diagnostic testsN Iznaga Escobar, J Solozabal Armstrong, G Núnez Gandolff, et al.
Nuclear Medicine Communications|December 5, 2002
A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptorK A Vallis, R M Reilly, P Chen, et al.
Methods and Findings in Experimental and Clinical Pharmacology|March 6, 2003
Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodiesA K Mishra, N Iznaga-Escobar, R Figueredo, et al.
Hybridoma|June 8, 2001
Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary studyT Crombet, O Torres, V Rodríguez, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Methods and Findings in Experimental and Clinical Pharmacology|January 6, 2005
(99m)Tc-labeled murine ior C5 monoclonal antibody in colorectal carcinoma patients: pharmacokinetics, biodistribution, absorbed radiation doses to normal organs and tissues and tumor localizationN Iznaga-Escobar, M Ramos-Suzarte, A Morales-Morales, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 26, 1998
Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearancesN Iznaga-Escobar, L A Torres Arocha, A Morales Morales, et al.
Nuclear Medicine and Biology|February 18, 1998
Technetium-99m direct radiolabeling of monoclonal antibody ior egf/r3A A Morales, F Z Crespo, G N Gandolff, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 31, 2001
Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptorT Crombet, O Torres, E Neninger, et al.
International Immunopharmacology|May 12, 2004
Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell lineM Tejuca, I Díaz, R Figueredo, et al.
Nuclear Medicine and Biology|April 25, 2000
Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studiesA A Morales, J Ducongé, D Alvarez-Ruiz, et al.
Journal of Immunological Methods|September 13, 1996
Multianalytical system (MAS): software for enzyme-linked immunosorbent assay (ELISA) data processing with applications to screening and diagnostic testsN Iznaga Escobar, J Solozabal Armstrong, G Núnez Gandolff, et al.
Nuclear Medicine Communications|December 5, 2002
A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptorK A Vallis, R M Reilly, P Chen, et al.
Methods and Findings in Experimental and Clinical Pharmacology|March 6, 2003
Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodiesA K Mishra, N Iznaga-Escobar, R Figueredo, et al.
Hybridoma|June 8, 2001
Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary studyT Crombet, O Torres, V Rodríguez, et al.
Pageof 3